Cynata confirms receipt of indicative, non-binding proposal
19 juil. 2019 07h00 HE
|
Cynata Therapeutics Limited
MELBOURNE, Australia, July 19, 2019 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: CYP) (“Cynata” or, the “Company”), a clinical-stage biotechnology company specializing in cell therapeutics,...
Cynata Receives Favourable Advice from UK MHRA on CLI Clinical Trial
12 mars 2019 09h03 HE
|
Cynata Therapeutics Limited
MELBOURNE, Australia, March 12, 2019 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that...
Cynata Completes Clinical Study Report for Phase 1 Trial of CYP-001 in GvHD
18 déc. 2018 08h15 HE
|
Cynata Therapeutics Limited
MELBOURNE, Australia, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specializing in cell therapeutics, is pleased to announce that...
NHMRC to Fund Major Phase 2 Clinical Trial of Cynata’s Cymerus™ MSCs in Patients with Osteoarthritis
13 déc. 2018 08h15 HE
|
Cynata Therapeutics Limited
MELBOURNE, Australia, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that...
Results of Cynata’s World-First GvHD Clinical Trial Accepted for Presentation at American Society of Hematology Annual Meeting
02 nov. 2018 08h45 HE
|
Cynata Therapeutics Limited
MELBOURNE, Australia, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specializing in cell therapeutics, is pleased to announce that...
Engineered Cymerus™ MSCs Demonstrate Anti-Cancer Effects in Preclinical Studies
18 oct. 2018 14h00 HE
|
Cynata Therapeutics Limited
Positive results in preclinical models support the use of the Cymerus platform to target various cancers MELBOURNE, Australia, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX:...
Cynata’s Cymerus™ MSCs Ameliorate Cytokine Release Syndrome in Preclinical Study
19 sept. 2018 08h00 HE
|
Cynata Therapeutics Limited
• Cymerus MSCs demonstrate substantial protection against CRS symptoms, a serious adverse reaction caused by cancer immunotherapies such as CAR-T MELBOURNE, Australia, Sept. 19, 2018 (GLOBE...
Cynata CYP-001 Stem Cell Therapy Meets All Safety and Efficacy Endpoints in Phase 1 Trial in GvHD
30 août 2018 08h00 HE
|
Cynata Therapeutics Limited
MELBOURNE, Australia, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX: CYP) is pleased to announce that CYP-001, its lead...
Cynata Reports Positive 28-day Data From Cohort B of Phase 1 Trial of CYP-001 in GvHD
21 juin 2018 08h00 HE
|
Cynata Therapeutics Limited
MELBOURNE, Australia, June 21, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX:CYP) is pleased to announce positive safety and...
Cynata Reports Positive Six-Month Data from Cohort A in Phase 1 Trial of CYP-001 in GvHD
12 juin 2018 09h38 HE
|
Cynata Therapeutics Limited
MELBOURNE, Australia, June 12, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX:CYP) is pleased to announce positive safety and...